Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Normative Datasets for Assessments Planned for Mild Traumatic Brain Injury (NORMAL)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2013 by Intermountain Health Care, Inc.
Sponsor:
Collaborators:
U.S. Army Medical Research and Materiel Command
The EMMES Corporation
Intermountain Health Care, Inc.
Evans Army Community Hospital
Information provided by (Responsible Party):
Lindell Weaver, Intermountain Health Care, Inc.
ClinicalTrials.gov Identifier:
NCT01925963
First received: August 16, 2013
Last updated: October 29, 2013
Last verified: October 2013
  Purpose

The purpose of the research study is to collect information about brain function and structure among active duty military personnel or civilians who are healthy. Researchers want to develop a database from normal volunteers that will be used in comparison with a similar database from active duty military with post-concussive syndrome (PCS) from a mild traumatic brain injury. Findings from this study may be used to design larger studies that will evaluate whether hyperbaric oxygen treatments actually improve PCS.

Participants in this study will undergo numerous tests to assess physical, mental, and intellectual health and how they might change over time. Participants will wear heart and activity monitors, undergo brain imaging, provide blood and urine for laboratory testing, and have vision, hearing, balance, and muscle function tests. They will also complete a number of questionnaires and interviews. This battery of tests will be repeated twice more over the course of 6 months.


Condition
Focus: Healthy Adults Without Brain Injury

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Development of Normative Datasets for Assessments Planned for Use in Patients With Mild Traumatic Brain Injury (NORMAL)

Resource links provided by NLM:


Further study details as provided by Intermountain Health Care, Inc.:

Primary Outcome Measures:
  • Change in neuropsychological test scores across time [ Time Frame: Baseline and 13 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in neuropsychological test scores across time [ Time Frame: Baseline and 6 months ] [ Designated as safety issue: No ]
  • Change in cerebral blood flow by computed tomography angiography [ Time Frame: Baseline and 6 months ] [ Designated as safety issue: No ]
  • Change in brain anatomical structures by quantitative magnetic resonance imaging [ Time Frame: Baseline and 6 months ] [ Designated as safety issue: No ]
  • Change in brain activation by functional magnetic resonance imaging [ Time Frame: Baseline and 6 months ] [ Designated as safety issue: No ]
  • Change in visual refractive error [ Time Frame: Baseline and 13 weeks ] [ Designated as safety issue: No ]
  • Change in visual refractive error [ Time Frame: Baseline and 6 months ] [ Designated as safety issue: No ]
  • Change in sleep quality total score by Pittsburgh Sleep Quality Index [ Time Frame: Baseline and 13 weeks ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Serum and plasma will be collected and frozen for future analyses. Future work may examine DNA, chronic neuro-response biomarkers, plasma- and leukocyte-based markers of TBI using a number of modern molecular techniques to examine the expression profiles of genes, proteins, and other macromolecules and to correlate these profiles to clinical outcomes, and genotypes.


Estimated Enrollment: 75
Study Start Date: October 2013
Estimated Study Completion Date: February 2016
Estimated Primary Completion Date: February 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts
Normal cohort
Normal, healthy adults without history of brain injury

Detailed Description:

The primary purpose of this study will develop a database from normal healthy participants for the same outcomes used in a program of studies of hyperbaric oxygen (HBO2) vs. sham control in participants with persistent post-concussive symptoms. This study will characterize the distribution of responses and change in responses over time for each of the outcomes and will examine associations between measures within a given normal participant and across participant characteristics such as age and gender. It will evaluate the test-retest reliability of a series of assessments anticipated for use in the primary, secondary, and exploratory outcomes of this program of studies.

A secondary purpose of this study is to compare normative values to results from randomized exploratory studies of HBO2 vs. sham control in participants with persistent post-concussive symptoms. Also, investigators will examine relationships between outcome measures from normal participants (with respect to clinical equivalence, participant burden, and risk) and compare to associations observed in other studies.

In this study, normal, healthy, non-brain injured civilians and military participants (active or inactive) will undergo a battery of outcome assessments at defined test intervals to replicate the assessment battery used in a program of studies investigating the safety of HBO2 in patients with post-concussive symptoms following mild traumatic brain injury (TBI).

The planned comprehensive assessments will obtain robust neuropsychological, physiological, and neuroimaging data. Other evaluations will include laboratory testing and evaluations of the auditory, vestibular, and visual systems. Neuroimaging (magnetic resonance imaging and computed tomography angiography) will be assessed in participants at baseline and 6 months. Neurological function and electroencephalography (EEG) will be assessed at baseline only. All other in-person outcome measures will be assessed in participants at baseline, at 13 weeks, and 6 months.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Normal, healthy, non-brain injured civilians and military participants (active or inactive)

Criteria

Inclusion Criteria:

  • Active duty or civilian in the Colorado Springs area.
  • Men 18-65 years old and women 18-35 years old at the time of enrollment.
  • Able to speak and read English, as primary language.
  • Agrees to, and appears able to participate in all outcome assessments.
  • Agrees to provide blood samples for laboratory tests and specimen banking.
  • Demonstrates the ability to offer informed consent and signs the study informed consent document.
  • No known brain imaging abnormalities.
  • Known history of full term non-complicated birth.
  • Estimated glomerular filtration rate (eGFR) >90.

Exclusion Criteria:

  • Prisoners.
  • Pregnant Women.
  • Minors.
  • Civilian participants with planned leave conflicting with study visits or relocation within 6 months of study enrollment, and unwilling or unable to return for follow up.
  • Active duty participants with planned leave or deployment conflicting with assessment intervals.
  • Any lifetime history of brain injury.
  • Diagnosis of, or a persistent history of, or symptoms of a neurological disorder (e.g., tinnitus, vertigo, chronic fatigue, numbness, tingling, chronic migraine, fibromyalgia, multiple sclerosis).
  • Active therapy for affective disorders, behavioral disorders, or psychological disorders.
  • Diagnosis of diabetes mellitus
  • Current complaints of brain injury symptoms such as cognitive or affective problems.
  • Diagnosis of recurrent migraine or cluster headaches that are under medical management.
  • Headaches that occur more than two times per week.
  • Recurrent dizziness that requires medical management.
  • Dizziness more than two times per week.
  • History of theater or war zone activity that placed the participant within a combat zone environment.
  • Diagnosis of PTSD or sub-clinical post-traumatic symptoms.
  • Known neuroimaging abnormalities.
  • Use of daily prescription drugs that could impact a normal outcome (e.g., beta blockers, antidepressants), with the following exceptions:
  • Participants who are 45 or more years old may be taking statins or ACE inhibitors.
  • Oral or injectable contraceptives are permitted
  • Participants <45 years old who are taking any daily prescriptions (exception - oral or injectable contraceptives)
  • Known atrial septal defect.
  • History of hydrocephalus/microcephaly/macrocephaly.
  • History of developmental delay or learning disorder as a child.
  • Women who are breastfeeding.
  • Women of childbearing potential who do not agree to practice an acceptable form of birth control during the study period.
  • Allergy to iodine-based contrast dye (exclusion criteria for neuroimaging assessment measures).
  • Those who are unable to participate fully in outcome assessments unless enrollment is reviewed and approved (in writing) by the Study Director.
  • Binocular vision not correctable to 20/50.
  • Deafness in both ears defined as 90 decibel hearing loss or greater through speech frequencies.
  • Anxiety or claustrophobia precluding participation in neuroimaging or vestibular procedures.
  • History of therapeutic ionizing radiation to the head.
  • Foreign material in head that would interfere with brain imaging.
  • Foreign material within the individual that poses risk from MRI.
  • History of illicit drug use, except remote, non-habitual use of marijuana.
  • History in the last year, of alcohol abuse.
  • Current positive urine test for an illicit substance(s).
  • Active or prior malignancy except basal cell carcinoma within the last 5 years.
  • Unable to abstain from caffeine or tobacco products for at least a 2-hour interval.
  • Concurrent enrollment in any other research trial.
  • Unable or unwilling to cease participation in sports or activities in which head injury is likely (e.g., mixed martial arts, boxing) during the study period.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01925963

Contacts
Contact: Lindell K. Weaver, MD 801-408-3623 lindell.weaver@imail.org

Locations
United States, Colorado
Evans Army Community Hospital Recruiting
Colorado Springs, Colorado, United States, 80913
Contact: Susan Churchill, APRN-NP    855-408-3614    susan.churchill@imail.org   
Contact: Robert C. Price, MD    719-576-1832    robert.c.price28.mil@mail.mil   
Principal Investigator: Robert C. Price, MD         
Outcomes Assessment Center Recruiting
Colorado Springs, Colorado, United States, 80906
Contact: Susan Churchill, APRN-NP    855-408-3614    susan.churchill@imail.org   
Contact: Robert C. Price, MD    719-576-1832    robert.c.price28.mil@mail.mil   
Principal Investigator: Robert C. Price, MD         
Sponsors and Collaborators
Lindell Weaver
U.S. Army Medical Research and Materiel Command
The EMMES Corporation
Intermountain Health Care, Inc.
Evans Army Community Hospital
Investigators
Principal Investigator: Robert C Price, MD Evans Army Community Hospital
  More Information

Publications:
Responsible Party: Lindell Weaver, Study Director, Intermountain Health Care, Inc.
ClinicalTrials.gov Identifier: NCT01925963     History of Changes
Other Study ID Numbers: S-11-16
Study First Received: August 16, 2013
Last Updated: October 29, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Intermountain Health Care, Inc.:
Normal
Traumatic brain injury
Neuroimaging
Hyperbaric oxygen
Neurobehavioral symptom inventory

Additional relevant MeSH terms:
Brain Injuries
Brain Diseases
Central Nervous System Diseases
Craniocerebral Trauma
Nervous System Diseases
Trauma, Nervous System
Wounds and Injuries

ClinicalTrials.gov processed this record on November 25, 2014